Astria Therapeutics (ATXS) 10-Q2020 Q3 Quarterly report

Filed: 12 Nov 20, 4:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abdominal, Absent, advisor, choose, conference, consummated, diarrhea, exhaust, forward, Ladenburg, maximize, mild, moving, pain, proven, rash, Thalmann, vomiting, wind

Removed: acceleration, account, accuracy, achievement, acid, activate, activated, advocacy, ambulation, amino, attract, Becker, biomarker, BMD, bone, cardiac, cellular, central, CF, chronically, combined, composite, composition, conditional, conjugate, consistency, controlled, corticosteroid, cysteamine, cysteine, cystic, default, deflazacort, degeneration, degradation, depressed, DHA, digesting, directed, directionally, disadvantage, disorder, diversify, docosahexaenoic, durability, dysferlin, dysferlinopathy, dystrophin, EC, EMFLAZA, eteplirsen, exceeded, expression, fatal, fatty, foundation, foundational, fourth, gene, goal, grow, half, headcount, heart, hiring, host, imaging, impacting, increasing, inflammation, inflammatory, internationally, intervention, Italfarmaco, Jain, launched, leg, life, LinkerTM, magnetic, measure, measuring, mechanism, Metabolized, mice, Miyoshi, model, MoveDMD, MRI, muscle, myopathy, myostatin, naturally, neuromuscular, nonsense, notified, NSAA, nuclear, observed, occurring, operational, overhead, packaged, participating, past, pipeline, pooled, prednisone, preserved, productivity, progressive, PTC, randomized, Rationally, recycling, reducing, reflecting, resonance, ReveraGen, Safely, salicylic, Santhera, Sarepta, science, score, sequential, servicing, setback, skeletal, subjecting, supporting, supportive, targeting, transitioned, translarna, treated, unsaturated, vulnerability, week

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ATXS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Catabasis Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2020	/s/ JILL C. MILNE, PH.D.
	Jill C. Milne, Ph.D.
	President and Chief Executive Officer (Principal Executive Officer)

Date: November 12, 2020	/s/ NOAH C. CLAUSER
	Noah C. Clauser
	Chief Financial Officer (Principal Financial Officer)